Date | 22 July 2020 – 13 April 2023 |
---|---|
Location | China |
Cause | COVID-19 pandemic in mainland China |
Target | Immunization against COVID-19 |
Organized by | Joint Prevention and Control Mechanism in Response to the COVID-19 Pandemic of the State Council (headquartered at National Health Commission) |
Participants | 3,491,077,000 [1] (total doses administered) |
Outcome | 1,310,292,000 [1] (total vaccinated) 1,276,760,000 [1] (fully vaccinated) |
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
COVID-19 vaccination in mainland China is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mainland China, in response to the ongoing pandemic in the region.
As of July 2022, it is estimated that about 89.7% of the country's population has received a vaccine, and about 56% of the population has received a booster dose. [2]
In June 2020, the Sinopharm BIBP vaccine (BBIBP-CorV) was authorized for emergency use in China. On July 22, Chinese authorities started the emergency use of COVID-19 vaccines. [3]
On December 15, 2020, the COVID-19 vaccination for people under high risk started in China. [4] On December 19, 2020, the National Health Commission (NHC) said that there has been 1 million doses of COVID-19 vaccine administered in China as of the day, and no serious adverse reactions were observed. [5]
On December 31, 2020, NHC announced that the Sinopharm BIBP vaccine has been approved through the conditional marketing authorization process, and more than 3 million doses of COVID-19 vaccine has been administered in China. [6] At the same time, NHC declares that COVID-19 vaccination is free to Chinese citizens. [7]
On January 27, 2021, NHC said that the vaccination is being carried out in order, and there has been 22.767 million doses of COVID-19 vaccine administered in China as of January 26. [8]
On March 1, 2021, Zhong Nanshan said that the vaccination rate of COVID-19 vaccine in China was currently 3.56%, and the Chinese Center for Disease Control and Prevention hoped the rate reach 40% by the end of June 2021. [9]
Since late March 2021, the authorities has accelerated the promotion of free COVID-19 vaccination for the whole population. [4] On March 22, 2021, Sun Chunlan, the Vice Premier of the State Council, stated that COVID-19 vaccination in China should be accelerated and the vaccination rate should be increased. [10] On March 24, 2021, NHC announced that the number doses of COVID-19 vaccine administered will be daily reported on its website and social media account since that day. [11] On March 29, 2021, NHC released the first version of the COVID-19 Vaccine Technology Guide. [12]
On April 21, 2021, NHC stated that more than 200 million doses of COVID-19 vaccine has been administered in China, and 80% of doctors and nurses has been vaccinated. [13]
On May 14, 2021, NHC restated that the COVID-19 administration progress should be accelerated due to the proportion of mutated SARS-CoV-2 and the re-appearance of local cases. [14]
On June 19, 2021, NHC announced that more than 1.01489 billion doses of COVID-19 vaccine has been administered in China. [15]
While public authorities have mandated lockdowns and mandatory mass testing for areas with infection, there has not been any rule to making vaccination mandatory. Some facilities within China have made vaccination mandatory for entry, including things like movie theatres, fitness centres, internet bars, museums and libraries. [16]
In July 2022, according to official figures, while 89% had received 2 doses, only 56% of eligible people had received a booster dose. Furthermore, this was even lower among vulnerable elderly age groups, with only 19.7% of people over the age of 80 having received a booster dose. According to BBC reporting, this may have been attributed to public confidence in the ability of authorities to control outbreaks, the narrative presented by public authorities within China that the virus was mainly an overseas problem as well as some doctors within China who warned vulnerable people of the health risks of the vaccine. [16]
As of | Doses administrated (in million) | References |
---|---|---|
Dec 19 (2020) | >1 | [5] |
Dec 31 (2020) | >3 | [6] |
Jan 27 (2021) | 22.767 | [8] |
Feb 9 | 40.52 | [17] |
Mar 15 | 64.98 | [18] |
Mar 28 | 102.417 | [DR 1] |
Apr 21 | 204.191 | [DR 2] |
May 7 | 308.226 | [DR 3] |
May 16 | 406.938 | [DR 4] |
May 23 | 510.858 | [DR 5] |
May 28 | 602.991 | [DR 6] |
Jun 2 | 704.826 | [DR 7] |
Jun 8 | 808.962 | [DR 8] |
Jun 14 | 904.134 | [DR 9] |
Jun 19 | 1,010.489 | [DR 10] |
Jun 24 | 1,120.643 | [DR 11] |
Jun 28 | 1,206.714 | [DR 12] |
July 4 | 1,305.499 | [DR 13] |
July 14 | 1,414.609 | [DR 14] |
July 22 | 1,507.605 | [DR 15] |
July 28 | 1,601.249 | [DR 16] |
August 3 | 1,708.356 | [DR 17] |
August 10 | 1,808.092 | [DR 18] |
August 18 | 1,900.127 | [DR 19] |
August 26 | 2,003.914 | [DR 20] |
As of November 21, 2022, seven vaccines have been approved in mainland China through conditional marketing authorization or emergency use authorization.
In 2021 Nature reported that "studies have questioned the length of protection" that domestic vaccines such as CoronaVac and Sinopharm offer, especially when compared to mRNA vaccines. [19] A 2022 meta-analysis found about 65% vaccine effectiveness against infection for CoronoVac, compared with about 90% for Pfizer and 98% for Moderna. [20] Some analysts have criticized China's reluctance to import mRNA vaccines. [21]
Vaccine | Type | Made by | Origin | Dose required for vaccination | Effective rate (Phase III) | Approval | Deployment | WHO Listed |
---|---|---|---|---|---|---|---|---|
Sinopharm BIBP | Inactivated | Beijing Institute of Biological Products | China | 2 doses [22] | 78.1% [23] | Conditional (December 31, 2020) [24] | December 31, 2020 | May 7, 2021 |
CoronaVac | Inactivated | Sinovac Biotech | China | 2 doses [22] | 50.7% - 83.5% [25] [26] | Conditional (February 5, 2021) [27] | February 5, 2021 | June 1, 2021 |
Sinopharm WIBP | Inactivated | Wuhan Institute of Biological Products | China | 2 doses [22] | 72.8% [23] | Conditional (February 25, 2021) [28] | February 25, 2021 | |
KCONVAC | Inactivated | Kangtai Biological Products Co. Ltd. | China | 2 doses [22] | — | EUA (May 14, 2021) [29] | June 1, 2021 | |
Covidful | Inactivated | Institute of Medical Biology, Chinese Academy of Medical Sciences | China | 2 doses [22] | — | EUA (June 9, 2021) [30] | June 9, 2021 | |
Convidecia | Viral vector | CanSino | China | 1 dose [22] | 65.7% [31] | Conditional (February 25, 2021) [32] | February 25, 2021 | May 19, 2022 [33] |
ZIFIVAX | Subunit | Zhifei Bio-tech | China | 3 doses [22] | 82% [34] [35] | EUA (March 10, 2021) [36] | March 10, 2021 | |
The Pfizer–BioNTech COVID-19 vaccine, agented by Fosun Pharma in mainland China, is waiting for approval. [37]
Vaccine | Type | Made by | Origin | Dose required for vaccination | Effective rate (Phase III) | Approval | Deployment | WHO Listed |
---|---|---|---|---|---|---|---|---|
Comirnaty | mRNA | BioNTech and Fosun Pharma | Germany | Waiting for Approval [37] | December 31, 2020 |
The COVID-19 pandemic in Hubei was first manifested by a cluster of mysterious pneumonia in Wuhan, the provincial capital of Hubei, China. A Wuhan hospital notified the local center for disease control and prevention (CDC) and health commissions on December 27, 2019. On December 31, Wuhan CDC admitted that there was a cluster of unknown pneumonia cases related to the Huanan Seafood Wholesale Market after the unverified documents appeared on the Internet. The potential disease outbreak soon drew nationwide attention including that of the National Health Commission (NHC) in Beijing which sent experts to Wuhan on the following day. On January 8, a new coronavirus was identified as the cause of the pneumonia. The sequence of the virus was soon published on an open-access database. Measures taken by China have been controversial. They were praised by the World Health Organization (WHO) for improvements over SARS-CoV-2 responses, but maligned by many in the international community for being slow to publicly disclose key facts or deceptive about the outbreak and for aggressively censoring information relating to the outbreak and public discontent from citizens online.
The COVID-19 pandemic in Shanghai is a part of the worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first confirmed in Shanghai on 20 January 2020. As of 14 October 2022, 65,641 confirmed cases cumulatively occurred in the city, of which 3,045 cases were imported from abroad. Of the 96 active hospitalized cases ending at midnight, 94 were in stable condition and 1 was in critical condition; 61,600 had cumulatively recovered and been discharged, and 595 died.
The COVID-19 pandemic reached the province of Henan, China on 21 January 2020.
The COVID-19 pandemic reached the province of Sichuan, People's Republic of China on 20 January 2020, with its first case confirmed on the next day.
Zhang Wenhong is a Chinese physician, and a member of the Chinese Communist Party. He is the Director and Party Branch Secretary of the Department of Infectious Diseases at Huashan Hospital affiliated to Fudan University, the Director of the Internal Medicine Department of the Shanghai Medical College, and also the leader of the Shanghai Medical Treatment Experts Group, deputy director of the Shanghai Institute of Liver Diseases, and standing committee member of the Infectious Disease Branch of the Chinese Medical Association.
Zhang Jixian is a Chinese pulmonologist. She is known to have discovered SARS‑CoV‑2, and was the director of the Department of Respiratory Medicine of Hubei Provincial Hospital of Integrated Chinese & Western Medicine. She is also a member of the Chinese Communist Party.
This article documents the situation of the COVID-19 pandemic in Inner Mongolia, the People's Republic of China.
The COVID-19 epidemic in Xinjiang Uyghur Autonomous Region is part of the worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). On 23 January 2020, the local government confirmed the first two case in Urumchi, the capital city of Xinjiang.
This article documents the situation of the COVID-19 pandemic in Liaoning Province, People's Republic of China.
The COVID-19 pandemic in Beijing is part of the worldwide pandemic of the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease first reached Beijing on 20 January 2020.
This article presents official statistics gathered during the COVID-19 pandemic in mainland China.
DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine candidate developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong.
COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country.
The COVID-19 pandemic reached the province of Fujian, China, on January 22, 2020.
The COVID-19 pandemic reached the province of Zhejiang, China.
The COVID-19 pandemic reached the province of Shandong, China.
The COVID-19 pandemic reached the province of Hebei, China.
The COVID-19 pandemic reached the province of Jiangxi, China.
The COVID-19 pandemic reached the Ningxia Hui Autonomous Region, China in 2020.
The COVID-19 pandemic reached the municipality of Tianjin, China, in January 2020.